{"id":"W2146956830","doi":"10.1136/gut.2005.083113","title":"Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy","year":2006,"lang":"en","type":"article","venue":"Gut","topic":"Hepatitis C virus research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Roche (Canada); University of Manitoba; Canadian Society of Intestinal Research; Queen Elizabeth II Health Sciences Centre; University of Alberta; BC Centre for Disease Control; University Health Network; Toronto General Hospital; Royal Victoria Hospital; Vancouver Hospital and Health Sciences Centre","funders":"Jewish General Hospital; London Health Sciences Centre; Hamilton Health Sciences","keywords":"Ribavirin; Medicine; Internal medicine; Peginterferon alfa-2a; Gastroenterology; Population; Cohort; Hepatitis C; Interferon; Hepatitis C virus; Genotype; Chronic hepatitis; Clinical endpoint; Immunology; Randomized controlled trial; Virus","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002784408,0.0003267681,0.0006008337,0.000360439,0.00006653752,0.00006581058,0.0002963569,0.000195803,0.001189697],"category_scores_gemma":[0.00008944589,0.0002964733,0.0001407843,0.0003485432,0.0001289933,0.0002109998,0.0001456255,0.0005567056,0.0009884898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002044915,"about_ca_system_score_gemma":0.0003643548,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01141159,"about_ca_topic_score_gemma":0.01075722,"domain_scores_codex":[0.9971771,0.0002086023,0.0006201607,0.0005736527,0.0006409222,0.0007795522],"domain_scores_gemma":[0.9988508,0.00006059242,0.0001064009,0.0006438257,0.0001638676,0.0001744994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006744538,0.0004137053,0.8703542,0.0001420015,0.00005449483,0.0001552401,0.0004851265,0.00005949136,0.001882356,0.00005550597,0.01639592,0.1093275],"study_design_scores_gemma":[0.008217275,0.003011703,0.9038845,0.0005991971,0.00001662542,0.000005630074,0.00001431903,0.003227386,0.002292771,0.00007991835,0.07827567,0.000375052],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825383,0.001380346,0.000128013,0.0005770199,0.0002021118,0.001441255,0.00003490269,0.0001052559,0.01359281],"genre_scores_gemma":[0.9910805,0.001614369,0.00007758939,0.0002335357,0.0003353117,0.0001950107,0.0002031034,0.00008300688,0.006177627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1089525,"threshold_uncertainty_score":0.9999487,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02087390925188778,"score_gpt":0.3000198028442696,"score_spread":0.2791458935923818,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}